Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 2851 - 2900Novel Risk Calculator for Sentinel Node Positivity in Patients With Melanoma
As reported in the Journal of Clinical Oncology, Lo et al developed a novel risk calculator for sentinel node metastasis—the Melanoma Institute Australia Nomogram—that appears to more accurately predict risk of metastasis in patients with primary cutaneous melanoma than other commonly used risk...
Long-Term Outcomes With Pembrolizumab for Cisplatin-Ineligible Advanced Urothelial Cancer
As reported in the Journal of Clinical Oncology by Vuky et al, long-term follow-up in the phase II KEYNOTE-052 study has shown durable responses with first-line pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer, with higher response rates and longer survival in...
Addition of Rituximab to Standard Chemotherapy in Pediatric Patients With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B (also known as Lymphome Malin de Burkitt, or LMB) chemotherapy ...
Long-Term Survival Outcomes With Different Durations of Adjuvant Imatinib for Gastrointestinal Stromal Tumors
In a 10-year follow-up of the phase III SSGXVIII/AIO trial reported in JAMA Oncology, Heikki Joensuu, MD, and colleagues found that 3 years vs 1 year of adjuvant treatment with imatinib was associated with superior overall survival among patients with high-risk gastrointestinal stromal tumors. The ...
Effect of Radiation Boost to Residual Disease in High-Risk Neuroblastoma
In an analysis from the Children’s Oncology Group (COG) ANBL0532 study reported in the Journal of Clinical Oncology, Liu et al found that a radiotherapy boost to the gross residual tumor in patients with high-risk neuroblastoma did not appear to improve outcomes compared with patients in another...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On May 6, 2020, the oral mesenchymal-epithelial transition (MET) kinase inhibitor capmatinib was granted accelerated approval for the treatment of adult patients who have metastatic non–small cell lung cancer (NSCLC) with tumors that have a mutation that leads to MET exon 14 skipping, as detected...
Pomalidomide for Treatment of Kaposi Sarcoma
On May 14, 2020, pomalidomide was granted accelerated approval to treat adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and for Kaposi sarcoma in adult patients who are HIV-negative.1,2 Pomalidomide is available only through the restricted...
Brigatinib for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On May 22, 2020, brigatinib was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion...
ASCO Survey on Early Impact of COVID-19 on Performance of Oncology Clinical Trials
In an article published in JCO Oncology Practice, David Waterhouse, MD, MPH, of Oncology Hematology Care, Cincinnati, Ohio, and colleagues presented the results of a recent ASCO survey of clinical programs on the early impact of the COVID-19 pandemic on the performance of oncology clinical...
Ruxolitinib Improves Response Rates in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Allogeneic SCT
In the phase III REACH2 trial reported in TheNew England Journal of Medicine, Robert Zeiser, MD, of the Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Germany, and colleagues found that the JAK1/2 inhibitor ruxolitinib improved response rate...
Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Previously Untreated CLL
As reported inThe Lancet by Jeff P. Sharman, MD, of Willamette Valley Cancer Institute/US Oncology, Eugene, Oregon, and colleagues, the phase III ELEVATE-TN trial has shown significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs...
Ramucirumab Plus Erlotinib in Treatment of EGFR-Mutant Metastatic NSCLC
On May 29, 2020, ramucirumab was approved for use in combination with erlotinib for first-line treatment of metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation.1,2 Supporting Efficacy Data Approval was based on findings from the...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Olaparib for Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 19, 2020, olaparib was approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who experienced disease progression after treatment with...
Ripretinib in Previously Treated Advanced Gastrointestinal Stromal Tumor
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 15, 2020, the receptor tyrosine kinase inhibitor...
Results of a COVID-19 and Cancer Consortium (CCC19) Cohort Study
As reported in The Lancet by Kuderer et al, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of severe COVID-19 in patients with cancer is associated with such factors as age, comorbidities, performance status, hematologic malignancy, and...
Efficacy Outcomes With C-MTX in Newly Diagnosed Patients With Pediatric T-Cell Lymphoblastic Lymphoma
As reported in the Journal of Clinical Oncology by Hayashi et al, the Children’s Oncology Group AALL0434 study has shown “excellent” outcomes with Capizzi-based methotrexate/pegaspargase (C-MTX) treatment in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL). The addition...
Prognosis of Patients With Stage III Melanoma According to AJCCv8 vs Independent Cohorts
In a study reported in the Journal of Clinical Oncology, Garbe et al found that melanoma-specific survival rates for patients with stage III disease differed markedly in three independent cohorts compared with those reported in American Joint Committee on Cancer version 8 (AJCCv8) stage III...
Ivosidenib for IDH1-Mutant Advanced Glioma
In a phase I study reported in the Journal of Clinical Oncology, Mellinghoff et al found that ivosidenib was well tolerated in patients with IDH1-mutant advanced glioma and was associated with prolonged disease control in those with nonenhancing glioma. Study Details The study included 66 evaluable ...
Factors Associated With COVID-19 Infection Severity in Patients With Cancer: Wuhan City Study
In a retrospective cohort study reported in The Lancet Oncology, Tian et al identified factors associated with severity of illness in patients with cancer hospitalized for COVID-19 over a 2-month period in Wuhan. Study Details The study included all patients aged ≥ 18 years with any type of solid...
Salvage Nivolumab/Ipilimumab After Prior Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Renal Cell Carcinoma
In a study reported in the Journal of Clinical Oncology, Gul et al found that salvage therapy with nivolumab/ipilimumab was capable of producing a response after prior programmed cell death 1 (PD-1) pathway inhibitor therapy in some patients with metastatic renal cell carcinoma. Study Details The...
Cisplatin/Fluorouracil vs Carboplatin/Paclitaxel in Chemotherapy-Naive Patients With Advanced Anal Cancer
In an International Rare Cancers Initiative phase II trial (InterAAct) reported in the Journal of Clinical Oncology, Rao et al found that carboplatin/paclitaxel was associated with less serious toxicity and a trend toward improved overall survival vs cisplatin/fluorouracil in chemotherapy-naive...
First-Line Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for SCLC Brain Metastases
In a cohort analysis reported in JAMA Oncology, Rusthoven et al found that first-line stereotactic radiosurgery was associated with similar outcomes as whole-brain radiotherapy in patients with small cell lung cancer (SCLC) brain metastases. As stated by the investigators, “Although stereotactic...
Impact of Medicare OCM Reporting Requirements on Biomarker Testing and Treatment in Advanced NSCLC
In a study reported in JCO Oncology Practice, Emily H. Castellanos, MD, MPH, and colleagues found that the requirement for Medicare Oncology Care Model (OCM) practices to report biomarker testing of patients with advanced non–small cell lung cancer (NSCLC) has not substantially altered the...
UKCCMP Prospective Cohort Study of COVID-19 Mortality in Patients With Cancer
As reported by Lee et al in The Lancet, a prospective cohort study from the United Kingdom performed by the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that increased risk of COVID-19 mortality in patients with cancer is associated with such factors as age, sex, and comorbidities,...
Role of Genetic Mutations and Treatment Exposures in Increased Subsequent Malignancy Risk for Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Qin et al identified combinations of pathogenic germline mutations in DNA repair genes and cancer treatment exposures that increased risk of subsequent neoplasms in long-term survivors of childhood cancer. Study Details The study involved...
Tafasitamab Plus Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase II L-MIND trial reported in The Lancet Oncology, Gilles Salles, MD, and colleagues found that the combination of the Fc-enhanced anti-CD19 monoclonal antibody tafasitamab plus lenalidomide produced responses in patients with relapsed or refractory diffuse large B-cell lymphoma...
Ripretinib in Previously Treated Patients With Advanced GIST: INVICTUS Trial
As reported in The Lancet Oncology by Jean-Yves Blay, MD, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib prolonged progression-free survival vs placebo in patients with advanced gastrointestinal stromal tumors (GIST) whose...
HLA-DP Expression and Risk of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation
In a study reported in the Journal of Clinical Oncology, Petersdorf et al found that level of expression of patient HLA-DPB1 mismatches and number of mismatches affect risk of acute graft-vs-host disease (GVHD) after unrelated donor hematopoietic cell transplantation. Study Details The study...
Retrospective Study of Characteristics and Outcomes in Patients With Cancer Hospitalized With COVID-19 in Hubei
In a retrospective cohort study reported in The Lancet Oncology, Yang et al described clinical characteristics, outcomes, and risk factors for mortality in patients with cancer hospitalized with COVID-19 over a 2-month period in Hubei, China. Study Details The study included 205 patients with...
Stereotactic Ablative Radiotherapy for Oligometastatic Cancer: Long-Term Findings From the SABR-COMET Trial
In a long-term follow-up of the phase II SABR-COMET trial reported in the Journal of Clinical Oncology, David A. Palma, MD, PhD, and colleagues found that the addition of stereotactic ablative radiotherapy (SABR) to palliative standard-of-care treatment in patients with oligometastatic cancers...
First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer
In the phase II portion of a single-center phase I/II trial reported in JAMA Oncology, Yu et al found that the combination of first-line osimertinib and bevacizumab resulted in a high rate of 1-year progression-free survival in patients with metastatic EGFR-mutant lung cancer. As stated by the...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented at the ASCO20 Virtual Scientific Program (Abstract 5077) and published as a brief report in JAMA Oncology, Ravi et al found that rechallenge with immune checkpoint inhibitor therapy was capable of producing responses in patients with metastatic renal cell carcinoma, including...
FGFR1–3 Inhibitor AZD4547 in Refractory Tumors Harboring FGFR Activating Mutations and Fusions
As reported in the Journal of Clinical Oncology by Chae et al, findings in a cohort of the phase II NCI-MATCH trial (EAY131, Subprotocol W) indicated that the oral inhibitor of fibroblast growth factor receptor 1, 2, and 3 (FGFR1–3), AZD4547, produced a small number of responses in patients with a...
Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab for Relapsed or Refractory CLL: ASCEND Trial
As reported in the Journal of Clinical Oncology by Ghia et al, the phase III ASCEND trial has shown prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in adult patients with relapsed or refractory...
Factors Associated With All-Cause 30-Day Mortality in Patients With Cancer Infected With COVID-19: CCC19 Database Analysis
As reported in The Lancet by Jeremy L. Warner, MD, and colleagues, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of all-cause mortality in patients with cancer infected with COVID-19 is associated with such factors as increased age, male sex, ...
Addition of Pemetrexed vs Vinorelbine to Adjuvant Cisplatin for Nonsquamous NSCLC
In the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant therapy with pemetrexed/cisplatin did not result in superior recurrence-free survival but was better tolerated than vinorelbine/cisplatin in patients with completely resected...
Pembrolizumab Plus Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
In a phase Ib study reported in the Journal of Clinical Oncology, Powell et al found that the addition of pembrolizumab to curative chemoradiotherapy was safe and associated with response in patients with locally advanced head and neck squamous cell carcinoma. Study Details The U.S. multicenter...
Meta-analysis of Outcomes With Checkpoint Inhibitor Treatment in Advanced Microsatellite Instability–High Cancers
A meta-analysis of published studies of immune checkpoint inhibition for advanced microsatellite instability–high (MSI-H) cancers—published as a brief report in JAMA Oncology by Petrelli et al—found high activity of these therapies across tumor types and evaluated agents. Study Details The...
Real-World Outcomes With Axicabtagene Ciloleucel Therapy in Relapsed or Refractory Large B-Cell Lymphoma
In a retrospective study reported by Nastoupil et al in the Journal of Clinical Oncology, researchers in the U.S. Lymphoma CAR T Consortium described outcomes with standard-of-care use of the autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel in patients ...
Breastfeeding Associated With Reduced Risk of Invasive Ovarian Cancer, Including High-Grade Serous Disease
In a pooled analysis reported in JAMA Oncology,1 Naoko Sasamoto, MD, MPH, of the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, and colleagues found that breastfeeding, even for durations of 1 to 3 months per birth, was associated with a significant reduction...
Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer
On April 29, 2020, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on...
Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Ibrutinib in Combination With Rituximab in Chronic Lymphocytic Leukemia
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Safety and Patient-Reported Outcomes From the IMpower150 Trial in Metastatic Nonsquamous NSCLC
A safety and patient-reported outcome analysis from the IMpower150 trial, reported in the Journal of Clinical Oncology by Martin Reck, PhD, and colleagues, indicated that atezolizumab plus bevacizumab and chemotherapy appeared to be a manageable and tolerable regimen when compared with atezolizumab ...
Outcomes With Minimally Invasive vs Open Esophagectomy in Routine Practice
In a Dutch study reported in the Journal of Clinical Oncology, Markar et al found that routine use of minimally invasive vs open esophagectomy for esophageal cancer was associated with increased risk of pulmonary complications and other adverse outcomes, contrary to the findings of the clinical...
Impact of the COVID-19 Pandemic on Pediatric Cancer Care in Latin America
In a commentary published in The Lancet Oncology, Vasquez et al presented results of a survey of pediatric oncologists/hematologists across Latin America, which showed an adverse early impact of the COVID-19 pandemic on pediatric cancer care. Study Details The study included a cross-sectional...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
Presalvage Radiotherapy PSA Levels and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology,1Robert T. Dess, MD, of the Department of Radiation Oncology, University of Michigan, Ann Arbor, and colleagues found that men with higher prostate-specific antigen (PSA) presalvage radiotherapy levels after prostatectomy had a...
